logo
logo
Sign in
Pooja Mahajan 2021-01-22
img

It is a proven medication that saves the life of a patient addicted to opioids.Opioid Antagonist Market: Key DriversEmergence of the opioid epidemic is one of the prominent factors driving the global opioid antagonists market.

The opioid epidemic refers to rise in number of deaths and hospitalization due to overdosage of opioids (including prescriptions, illicit drugs, and analogs).

Addiction to and misuse of opioids including pain-reliever opioids, heroin, and synthetic opioids lead to significant crisis on social, economic, and public health.Opioids are commonly prescribed for underlying causes of chronic pain such as cancer, trauma and injury cases, post-operative pain, and arthritis disorders.

This is also estimated to indirectly drive the market during the forecast period.Large number of drugs in clinical trials, new product development and commercialization, and regulatory guidelines to minimize the opioid crisis are factors projected to augment the market during the forecast periodRequest Brochure of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=B_id=78168Mu Opioid Receptor Segment to Dominate Global MarketIn terms of opioid receptor, the global opioid antagonist market can be classified into mu receptor, kappa receptor, delta receptor, and others.

The centrally acting opioid receptor segment is estimated to create lucrative opportunities during the forecast period.Naloxone is a commonly used centrally acting opioid receptor.

High prevalence of chronic pain; rise in number of hospitalizations due to chronic disorders, especially trauma and cancer cases; and opioid crisis in the U.S. are factors likely to boost the market in the region during the forecast periodAccording to the Centers for Disease Control and Prevention (CDC), approximately 50 million adults in the U.S. suffered from chronic pain and around 19.6 million adults were afflicted with high-impact chronic pain in 2016The opioid antagonist market in Asia Pacific is anticipated to expand at the highest CAGR during the forecast period.

collect
0
Pooja Mahajan 2021-01-22
img

It is a proven medication that saves the life of a patient addicted to opioids.Opioid Antagonist Market: Key DriversEmergence of the opioid epidemic is one of the prominent factors driving the global opioid antagonists market.

The opioid epidemic refers to rise in number of deaths and hospitalization due to overdosage of opioids (including prescriptions, illicit drugs, and analogs).

Addiction to and misuse of opioids including pain-reliever opioids, heroin, and synthetic opioids lead to significant crisis on social, economic, and public health.Opioids are commonly prescribed for underlying causes of chronic pain such as cancer, trauma and injury cases, post-operative pain, and arthritis disorders.

This is also estimated to indirectly drive the market during the forecast period.Large number of drugs in clinical trials, new product development and commercialization, and regulatory guidelines to minimize the opioid crisis are factors projected to augment the market during the forecast periodRequest Brochure of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=B_id=78168Mu Opioid Receptor Segment to Dominate Global MarketIn terms of opioid receptor, the global opioid antagonist market can be classified into mu receptor, kappa receptor, delta receptor, and others.

The centrally acting opioid receptor segment is estimated to create lucrative opportunities during the forecast period.Naloxone is a commonly used centrally acting opioid receptor.

High prevalence of chronic pain; rise in number of hospitalizations due to chronic disorders, especially trauma and cancer cases; and opioid crisis in the U.S. are factors likely to boost the market in the region during the forecast periodAccording to the Centers for Disease Control and Prevention (CDC), approximately 50 million adults in the U.S. suffered from chronic pain and around 19.6 million adults were afflicted with high-impact chronic pain in 2016The opioid antagonist market in Asia Pacific is anticipated to expand at the highest CAGR during the forecast period.